You can trust Advil Liqui-Gels to act fast to relieve your patient’s acute pain1,2
Advil Liqui-Gels act fast to relieve acute pain1
With demonstrated safety and proven efficacy, fast acting Advil Liqui-Gels are available in regular, extra strength, and mini formats.1,3,4
Advil Mini-Gels offer fast and effective pain relief in a smaller and easy to swallow format.2,3
Up to 40% of Canadians experience some difficulty swallowing pills.5* The mini size of Advil Mini-Gels makes them easy to swallow.
Ibuprofen is the non-steroidal anti-inflammatory ingredient in Advil products.2
* Advil Nielsen BASES Canada.5
Overall & GI Tolerability Profile
Ibuprofen comparative tolerability in a large-scale randomized trial
In the PAIN study, published in Clinical Drug Investigation, overall tolerability of ibuprofen was:2,4
- Statistically equivalent to that of acetaminophen
- Superior to that of ASA
This large scale randomized trial comparing nonprescription doses of ASA, acetaminophen, and ibuprofen in 8,677 adults measured rates of significant adverse events related to tolerability. The primary outcome measure was the number of patients with at least one significant adverse event, defined as an event that was serious, severe or moderate, resulted in a second physician consultation, led to cessation of treatment, or was of missing intensity. Statistical analysis tested for equivalence between ibuprofen and acetaminophen, and for difference with ASA. 2,4*
ASA = acetylsalicylic acid; GI = gastrointestinal.* This was a blinded, multicentre study in general practice of up to 7 days of ASA, acetaminophen (both up to 3 g daily) or ibuprofen (up to 1.2 g daily), administered for common painful conditions, using patient generated data with physician assistance. 1,108 general practitioners included 8,677 adults (2,900 ASA; 2,886 ibuprofen; 2,888 acetaminophen; 3 patients had no code label number). The main indications were musculoskeletal or back pain (48%), sore throat, the common cold and flu (31%).
When used as directed for acute pain, OTC ibuprofen is well tolerated2*
In the PAIN study, which included over 8,500 patients, total GI events (including dyspepsia) and abdominal pain were less frequent with ibuprofen (200 mg) compared to acetylsalicylic acid (500 mg) or acetaminophen (500 mg) (all p<0.035). 2,4
This large scale randomized trial comparing nonprescription doses of ASA, acetaminophen, and ibuprofen in 8,677 adults measured rates of significant adverse events related to tolerability. The primary outcome measure was the number of patients with at least one significant adverse event, defined as an event that was serious, severe or moderate, resulted in a second physician consultation, led to cessation of treatment, or was of missing intensity. Statistical analysis tested for equivalence between ibuprofen and acetaminophen, and for difference with ASA. 2,4*
ASA = acetylsalicylic acid; GI = gastrointestinal; OTC = over the counter.* This was a blinded, multicentre study in general practice of up to 7 days of ASA, acetaminophen (both up to 3 g daily) or ibuprofen (up to 1.2 g daily), administered for common painful conditions, using patient generated data with physician assistance. 1,108 general practitioners included 8,677 adults (2,900 ASA; 2,886 ibuprofen; 2,888 acetaminophen; 3 patients had no code label number). The main indications were musculoskeletal or back pain (48%), sore throat, the common cold and flu (31%).
Cardiovascular safety profile
Studies showed that cardiovascular risk of ibuprofen is dose-dependent and did not increase with use at OTC doses (≤1200mg/day):6-10
| Ibuprofen dose | Andersohn et al., 2006 | Garcia-Rodriguez,et al., 2008 | van Staa, et al., 2008 | Fosbøl et al., 2009 | McGettigan & Henry., 2011 |
| <1,200 mg/day | RR: 1.05 (95% CI: 0.91, 1.22) | ||||
| ≤1,200 mg/day | RR: 0.99 (95% CI: 0.81, 1.21) | RR: 1.00 (95% CI: 0.80, 1.25) | HR: 0.92 (95% CI: 0.86, 0.97 | RR: 1.05 (95% CI: 0.96, 1.15) |
* Long term continuous use may increase the risk of heart attack or stroke.2
CHD = coronary heart disease; CI = confidence interval; HR = hazard ratio; MI = myocardial infarction; NSAID = nonsteroidal anti-inflammatory drug; OTC = over the counter; RR = relative risk.
† Andersohn F and colleagues conducted a nested case-control study in a cohort of 486,378 persons registered within the United Kingdom General Practice Research Database with at least 1 prescription of an NSAID between June 1, 2000 and October 31, 2004. Rate ratios of acute MI associated with use of COX-2–selective and –nonselective NSAIDs were calculated. The duration of each NSAID prescription was determined by dividing the quantity of prescribed tablets by the number of tablets to be taken daily. “Current” exposure was defined as a NSAID prescription that lasted into the 14-day period before the index date. “Recent” exposure denoted a supply that ended between 15–183 days before the index date, and “past” exposure denoted a supply that ended between 184 days and 1 year before the index date. “Nonuse” was defined as no use of any NSAID during the year before the index date. Rate ratios appeared to increase with higher daily doses of COX-2 inhibitors and were also increased in patients without major cardiovascular risk factors.
Garcia Rodriguez LA and colleagues conducted a population-based, nested case-control analysis of medical records from The Health Improvement Network database in the United Kingdom. The risk of MI was assessed in 716,394 individuals 50–84 years of age between January 2000 and October 2005 (followed up on average of 4.1 years). NSAID exposure was categorized as: “current” when the supply of the most recent prescription lasted until the index date (day of first sign leading to hospitalization) or ended in the 7 days before the index date; “recent”, when it ended 8–90 days before the index date; “past”, when it ended 91–365 days before the index date; and “nonuse”, when there was no recorded use in the year before the index date. “Current use” was subdivided into: “single” when there was use of only one individual NSAID the month before the index date; “multiple” when the patient received prescriptions for 2 or more individual NSAIDs the week before the index date; and “switcher” when there was use of only one NSAID in the week before the index date, but there was use of at least one other NSAID 8–30 days before the index date.
van Staa TP and colleagues conducted a retrospective cohort study that included 729,294 patients from the UK General Practice Research Database (GPRD). The RR of MI was examined in patients that were ≥40 years of age at first NSAID prescription. Data collection started in 1987 and ended for this study in 2006, and the median follow-up for the NSAID cohort was 6.1 years. Patients were followed from the first NSAID prescription (the index date) to the patient’s death, patient’s transfer out of general practice, the last GPRD data collection available for the study (first quarter of 2006), or the date of the first selective COX-2 NSAID prescription, whichever came first. The total follow-up of NSAID users was divided into periods of “current” and “past” exposure, with patients moving between these two groups according to their NSAID use. “Current” exposure was defined as the period from the date of a NSAID prescription to the end of expected duration, plus 3 months. The expected duration of NSAID use was estimated using the daily dose as prescribed by the general practitioner and the number of NSAID tablets.
Fosbøl EL and colleagues conducted a historical cohort study using data from over 1 million healthy Danish individuals over the age of 10 that evaluated the risk of MI and death associated with NSAID use. Healthy is defined according to a history of no hospital admissions and no concomitant selected pharmacotherapy (refer to study for the complete list). NSAIDs were used for 9–34 days.
McGettigan P and Henry D conducted a systematic review of community-based controlled observational studies to determine the cardiovascular risks of NSAIDs. This review included 38 studies with ibuprofen. NSAID prescription was categorized as “current” if it covered a period that included the index day or continued to within 1 week or less of the index day (the day the adverse cardiac event occurred). The outcomes studied included MI, CHD related death or composite of MI, and CHD death.
Clinically proven efficacy for mild to moderate acute pain2
There is considerable evidence documenting the efficacy of 200 mg and 400 mg doses of ibuprofen in the treatment of mild to moderate pain in a range of pain models.2
One Advil is often all it takes to relieve mild to moderate pain including: 2
- Sore throat pain
- Headache & migraine
- Muscle aches
- Menstrual pain
- Toothache (dental pain)
Advil also reduces fever.
Clinically proven efficacy in headache pain
Advil (200 mg, 400 mg) has been clinically proven to effectively relieve headache pain.2
Journal of Clinical Pharmacology, 1996 (Schachtel BP et al.)
- A double blind, randomized study comparing ibuprofen 400 mg (N=153) vs. acetaminophen 1000 mg (N=151) and placebo (N=151) found that ibuprofen relieved headache pain significantly better than acetaminophen 1000 mg and placebo. Participants receiving ibuprofen 400 mg reported experiencing no pain significantly faster (at 1, 2, 3, and 4 hours post intake) than those receiving acetaminophen 1000 mg. Approximately, more than 3 times the percentage of subjects receiving ibuprofen 400 mg noted no pain compared to acetaminophen 1000 mg, 3 hours post dose.16*
Headache, 1988 (Schachtel BP et al.)
- A double blind, randomized study compared ibuprofen 400 mg (N=35) to placebo demonstrating a significant analgesic effect on headache within 30 minutes (N=35)17†
* At 30 minutes and 1, 2, 3, and 4 hours post dose, each patient completed the Headache Pain Intensity Scale and the Headache Pain Relief Scale.† Seventy subjects satisfied the admission criteria and included men (21 in treatment group and 15 in placebo) and women (15 in the treatment group and 20 in the placebo group) with a mean age of ~21 years of age. They were instructed to complete a Headache Diary when they experienced a muscle contraction headache. When the headache occurred, they were to swallow a single dose of study medication. Efficacy evaluations were done at 15, 30, 45, 60, 90, and 120 minutes after dosing.
Clinically proven efficacy in migraine pain2,18
Ibuprofen 400 mg has been clinically proven to be effective in relieving the pain of migraine headache and related functional disability.18*
Cochrane Database of Systematic Reviews, 2013 (Rabbie R et al.)
- In a review of 9 studies all participants had a diagnosis of migraines and most had a history of migraine symptoms for at least 12 months before entering the study18
- The proportion of participants experiencing headache relief at 2 hours with ibuprofen 400 mg was 57% vs. 25% with placebo18†
- The proportion of participants with relief from functional disability at 2 hours after ibuprofen 400 mg was 42% vs. 24% with placebo18‡
NNT = number needed to treat.* Included participants all had a diagnosis of migraine headaches according to International Headache Society criteria. The mean age of participants was 30 to 40 years of age in individual studies.† Proportion with ibuprofen is 57% (528/931; range 41% to 72%) and the proportion with placebo was 25% (224/884; range 7% to 50%).‡ The proportion of participants with relief of functional disability at 2 hours after ibuprofen 400 mg was 42% (245/583; range 18% to 76%). The proportion of participants with relief of functional disability at 2 hours after placebo was 24% (129/531; range 13% to 55%).
Jane wants fast, effective relief for her migraine pain
Jane* is always on the go. She balances work and family, travel, and friends. She’s active and positive. When a migraine starts to slow her down, she needs fast relief.
Her pain: migraine.
Advil Liqui-Gels act fast to relieve pain including migraine pain and its symptoms.1,2
Ibuprofen 200 mg† and 400 mg have been clinically proven effective in relieving the pain of migraine headache and related functional disability.18
* Fictional case study.† Excluding Advil Mini-Gels.
Recommend Advil to manage your patients’ acute pain
Advil Liqui-Gels
Advil Liqui-Gels act fast to relieve acute pain1Available in regular, extra strength, and mini formats.1,3,4
Advil — for all your patients’ acute pain relief needs
Advil — for all your patients’ acute pain relief needs
Learn more about the Advil product family range.
